Thalomid myeloma sNDA “approvable”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene's immunomodulatory drug Thalomid (thalidomide) has received a second "approvable" letter for treatment of multiple myeloma, the firm announces Nov. 15. FDA appears to be suggesting limiting the indication to newly diagnosed patients: "FDA has requested revised product labeling with the specific indication of newly diagnosed multiple myeloma and updated safety information, as well as some additional patient information to finalize its review," Celgene reports. The myeloma sNDA was originally submitted in December 2003; an initial approvable letter was issued in October 2004 (Pharmaceutical Approvals Monthly April 2005, In Brief). Thalomid is currently approved for treatment of erythema nodosum leprosum...
You may also be interested in...
Celgene Revlimid MDS filing
Celgene is requesting a priority review for its Revlimid (lenalidomide) NDA for treatment of transfusion-dependent patients with myelodysplastic syndromes with a 5q deletion chromosomal abnormality. A rolling submission was completed April 8, the company said. The submission is based on a Phase II trial in patients with the 5q deletion abnormality. Revlimid has fast track designation for MDS as well as multiple myeloma. The firm's Thalomid (thalidomide) sNDA for use in multiple myeloma has been "approvable" since October 2004...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.